Page last updated: 2024-10-25

cilostazol and Lupus Erythematosus, Systemic

cilostazol has been researched along with Lupus Erythematosus, Systemic in 1 studies

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guo, J1
Chen, W1
Wang, G1
Zhu, F1

Other Studies

1 other study available for cilostazol and Lupus Erythematosus, Systemic

ArticleYear
Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus.
    International journal of cardiology, 2015, Apr-15, Volume: 185

    Topics: Aged; Cilostazol; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Intermittent Claudi

2015